S. Kirkesseli

发表

Estimating Mass Balance for Inhaled Drugs in Humans: An Example with a VLA‐4 Antagonist, IVL745

B. Jensen, S. Rohatagi, Zhaopie Zeng, 2004, Journal of clinical pharmacology.

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.

S. Holgate, B. O'connor, H. Arshad, 2005, The Journal of allergy and clinical immunology.

Lack of Correlation between In Vitro Inhibition of CYP3A‐Mediated Metabolism by a PPAR‐γ Agonist and Its Effect on the Clinical Pharmacokinetics of Midazolam, an In Vivo Probe of CYP3A Activity

Y. Luo, J. Stevens, P. Zannikos, 2001, Journal of clinical pharmacology.

Single‐ and Multiple‐Dose Pharmacokinetics of Riluzole in White Subjects

P. Truffinet, G. Montay, Y. Roux, 1997, Journal of clinical pharmacology.

Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler

B. Jensen, S. Newman, S. Rohatagi, 2004, American journal of therapeutics.

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, British journal of clinical pharmacology.

Adverse events in phase-I studies: a report in 1015 healthy volunteers

A. Janin, S. Kirkesseli, M. Sibille, 1998, European Journal of Clinical Pharmacology.

A Comparison of the Pharmacokinetics and Tolerability of Riluzole after Repeat Dose Administration in Healthy Elderly and Young Volunteers

G. Montay, J. Gautier, P. Peeters, 1999, Journal of clinical pharmacology.

Dose‐proportional pharmacokinetics of terbinafine and its N‐demethylated metabolite in healthy volunteers

J. Kovarik, P. Grass, S. Kirkesseli, 1992, The British journal of dermatology.

Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects

S. Kirkesseli, J. Wiley, H. Humbert, 1995, Biopharmaceutics & drug disposition.

Dupilumab in persistent asthma with elevated eosinophil levels.

S. Wenzel, G. Yancopoulos, N. Stahl, 2013, The New England journal of medicine.

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, medRxiv.

Pharmacokinetics, Pharmacodynamics, and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, following Intravenous Administration in Healthy Male Volunteers

B. Jensen, S. Rohatagi, P. Zannikos, 2000, Journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1 Agonist, RPR749, in Healthy Subjects

B. Jensen, S. Rohatagi, C. Natarajan, 2004, American journal of therapeutics.

Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Cyclosporin A (ADI628) after Single and Repeated Administration in Healthy Male and Female Subjects and Asthmatic Patients

B. Jensen, S. Rohatagi, S. Kirkesseli, 2000, Journal of clinical pharmacology.

A Pilot Study to Assess the Feasibility of Collecting and Transmitting Clinical Trial Data with Mobile Technologies

Matthias Kruse, Nadir Ammour, Nicolas Bonnet, 2018, Digital Biomarkers.

A bridging study of fananserin in schizophrenic patients.

N. Cutler, J. Sramek, J. Hourani, 1998, Psychopharmacology bulletin.

Prediction of Hemodynamic Responses in Hypertensive and Elderly Subjects from Healthy Volunteer Data: The Example of Intravenous Nicardipine

J. Steimer, P. Francheteau, H. Merdjan, 2002 .